Join the Omalizumab group to help and get support from people like you.
Omalizumab News
Study Compares Benefits, Harms of Treatments for Chronic Hives
WEDNESDAY, July 23, 2025 – Omalizumab and remibrutinib may be the most effective treatments for reducing hives, itch, and swelling with chronic urticaria, according to a study published online July...
What Are The Best Treatments For Chronic Hives?
FRIDAY, July 18, 2025 — Hives can drive a person crazy, covering parts of the body with maddeningly itchy welts. Now, a new evidence review has identified the most effective treatments for people who ...
American Academy of Allergy, Asthma & Immunology, Feb. 28-March 3
The annual meeting of the American Academy of Allergy, Asthma & Immunology was held from Feb. 28 to March 3 in San Diego, drawing clinicians, academicians, allied health professionals, and others i...
FDA Approves Omlyclo (omalizumab-igec), an Interchangeable Biosimilar to Xolair
JERSEY CITY, N.J., March 9, 2025 /PRNewswire/ – Celltrion today announced the U.S. Food and Drug Administration (FDA) approved Omlyclo® (omalizumab-igec) as the first and only biosimilar designated a...
AAAAI: Omalizumab Superior to Oral Immunotherapy in Multifood Allergy
MONDAY, March 3, 2025 – Omalizumab is superior to oral immunotherapy (OIT) for multifood allergy, and most patients include dietary consumption (DC) of allergy-triggering foods after gaining...
FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies
South San Francisco, CA – February 16, 2024 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved...
FDA Approves Xolair (omalizumab) Prefilled Syringe for Self-Injection Across All Indications
South San Francisco, CA – April 12, 2021 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the...
Genentech Announces FDA Approval of Xolair (omalizumab) for Adults with Nasal Polyps
South San Francisco, CA – December 1, 2020 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) has approved the...
FDA Approves Genentech’s Xolair (omalizumab) for Allergic Asthma in Children
South San Francisco, CA – July 7, 2016 – Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Xolair...
FDA Medwatch Alert: Xolair (omalizumab): Drug Safety Communication - Slightly Elevated Risk of Cardiovascular and Cerebrovascular Serious Adverse Events
ISSUE: An FDA review of safety studies suggests a slightly increased risk of problems involving the heart and blood vessels supplying the brain among patients being treated with the asthma drug...
FDA Approves Xolair (omalizumab) for Chronic Idiopathic Urticaria
South San Francisco, Calif. – March 21, 2014 – Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration (FDA) approved Xolair (omalizumab) for the...
Further information
Related condition support groups
Urticaria, Hives, Nasal Polyps, Asthma - Maintenance, Chronic Rhinosinusitis with Nasal Polyps, Asthma